Popular Articles

Frankenman International Ltd Secures FDA Clearance For Its Entire CHEX Range Of Surgical Staplers
Frankenman International Ltd, the manufacturer and supplier of surgical instruments, announced that its entire CHEX™ range of surgical staplers had been granted FDA approval. This development complements the CE and ISO accreditation it has already acquired. FDA approval endorses Frankenman"s commitment to total quality in surgical stapling and wound closure devices, and further validates its position as a trusted alternative supplier in these markets.

DrugScope Welcomes National Treatment Agency Announcment Of Increased Funding For Drug Treatment
DrugScope has welcomed the National Treatment Agency for Substance Misuse"s announcement of an extra ÷£11.8m government investment in drug treatment.
News of the day
Series On The Status Of Public Health In Southeast Asia Launched By The Lancet
In these difficult times, when the global health community is facing the dangers of an important new influenza pandemic, a new partnership is forming. The lancet, one of the world÷“s leading medical journals has announced its partnership with the Rockefeller Foundation and the China Medical Board. Together they will develop a major series to evaluate the state of public health in Southeast Asia.
Nutrition

Inflammatory Molecules Promote Liver Scarring

Scarring of the liver, which can progress to cirrhosis and/or cancer of the liver, is caused by persistent liver damage, such as occurs in those with untreated hepatitis C or alcoholism. Although such scarring (fibrosis) develops in an inflammatory environment, the role of inflammatory molecules has not been well defined. However, a team of researchers at Columbia University, New York, and UCSD, La Jolla, has established that the proteins CCR1 and CCR5 and the soluble inflammatory molecules that bind to them promote the development of liver fibrosis in mice. The team, led by Robert Schwabe and Ekihiro Seki, observed that expression of the inflammatory molecules MIP-1-alpha, MIP-1-beta, and RANTES, and the proteins to which they bind (CCR1 and CCR5), was increased in 2 mouse models of liver fibrosis. Consistent with a role for these molecules in the development of liver fibrosis, preventing the inflammatory molecules binding CCR1 and CCR5 reduced liver fibrosis, as did eliminating expression of either CCR1 or CCR5. The latter experiments also identified the cells on which CCR1 and CCR5 expression is important for promoting liver fibrosis. As expression of RANTES, CCR1, and CCR5 was detected in the livers of patients with cirrhosis, the authors suggest that targeting CCR1 and CCR5 (for which there are already small molecule inhibitors in clinical development) might be a viable approach to prevent liver fibrosis. TITLE: CCR1 and CCR5 promote hepatic fibrosis in mice AUTHORS: Robert F. Schwabe Columbia University, New York, New York, USA. Ekihiro Seki University of California, San Diego, La Jolla, California, USA. View the PDF of this article at: https://www.the-jci.org/article.php?id=37444 Karen Honey Journal of Clinical Investigation JCI online early table of contents: June 15, 2009


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):